EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer

被引：976

作者：

Adrian P. Bracken ^{[1
]}

Diego Pasini ^{[1
]}

Maria Capra ^{[1
]}

Elena Prosperini ^{[2
]}

Elena Colli ^{[1
]}

Kristian Helin ^{[1
]}

机构：

[1] European Institute of Oncology, Department of Experimental Oncology, 20141 Milan

[2] FIRC Institute of Molecular Oncology, 20139 Milan

来源：

The EMBO Journal | 2003年 / 22卷 / 20期

关键词：

E2F; EED; EZH2; Polycomb; pRB;

D O I：

10.1093/emboj/cdg542

中图分类号：

学科分类号：

摘要：

Recent experiments have demonstrated that the Polycomb group (PcG) gene EZH2 is highly expressed in metastatic prostate cancer and in lymphomas. EZH2 is a component of the PRC2 histone methyltransferase complex, which also contains EED and SUZ12 and is required for the silencing of HOX gene expression during embryonic development. Here we demonstrate that both EZH2 and EED are essential for the proliferation of both transformed and non-transformed human cells. In addition, the pRB-E2F pathway tightly regulates their expression and, consistent with this, we find that EZH2 is highly expressed in a large set of human tumors. These results raise the question whether EZH2 is a marker of proliferation or if it is actually contributing to tumor formation. Significantly, we propose that EZH2 is a bona fide oncogene, since we find that ectopic expression of EZH2 is capable of providing a proliferative advantage to primary cells and, in addition, its gene locus is specifically amplified in several primary tumors.

引用

页码：5323 / 5335

页数：12

共 41 条

[31] Ren B., Cam H., Takahashi Y., Volkert T., Terragni J., Young R.A., Dynlacht B.D., E2F integrates cell cycle progression with DNA repair, replication and G<sub>2</sub>/M checkpoints, Genes Dev., 16, pp. 245-256, (2002)
[32] Rugarli E.I., Lutz B., Kuratani S.C., Wawersik S., Borsani G., Ballabio A., Eichele G., Expression pattern of the Kallmann syndrome gene in the olfactory system suggests a role in neuronal targeting, Nat. Genet., 4, pp. 19-26, (1993)
[33] Sage J., Mulligan G.J., Attardi L.D., Miller A., Chen S., Williams B., Theodorou E., Jacks T., Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization, Genes Dev., 14, pp. 3037-3050, (2000)
[34] Sherr C.J., DePinho R.A., Mitotic clock or culture shock?, Cell, 102, pp. 407-410, (2000)
[35] Suzuki A., Hemmati-Brivanlou A., Xenopus embryonic E2F is required for the formation of ventral and posterior cell fates during early embryogenesis, Mol. Cell, 5, pp. 217-229, (2000)
[36] Trimarchi J.M., Lees J.A., Sibling rivalry in the E2F family, Nat. Rev. Mol. Cell Biol., 3, pp. 11-20, (2002)
[37] Varambally S., Et al., The polycomb group protein EZH2 is involved in progression of prostate cancer, Nature, 419, pp. 624-629, (2002)
[38] Visser H.P.J., Gunster M.J., Kluin-Nelemans H.C., Manders E.M.M., Raaphorst R.M., Meijer C.J.L.M., Willemze R., Otte A.P., The Polycomb group protein EZH2 is upregulated in proliferating, culture mante cell lymphoma, Br. J. Haematol., 112, pp. 950-958, (2001)
[39] Wallrapp C., Muller-Pillasch F., Solinas-Toldo S., Lichter P., Friess H., Buchler M., Fink T., Gress T.M., Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene, Cancer Res., 57, pp. 3135-3139, (1997)
[40] Weinmann A.S., Bartley S.M., Zhang T., Zhang M.Q., Farnham P.J., Use of chromatin immunoprecipitation to clone novel E2F target promoters, Mol. Cell. Biol., 21, pp. 6820-6832, (2001)

← 1 2 3 4 5 →